Capromorelin for Recovery
Oral non-peptide ghrelin-receptor agonist; FDA-approved as a veterinary appetite stimulant.
Why Capromorelin for recovery?
Capromorelin is a small-molecule ghrelin agonist (GHSR1a) approved by the FDA for appetite stimulation in dogs (Entyce, 2016) and cats (Elura, 2020). Human Phase 2 trials in elderly sarcopenia showed modest gains in tandem-walk and lean mass before development was halted.
Recovery context: Accelerating soft-tissue, tendon, gut, and post-training repair. Capromorelin fits this goal because its category (Performance) and benefit profile align with the underlying mechanism.
Benefits relevant to recovery
- Stimulates appetite
- Raises GH/IGF-1
- Oral bioavailability
Reference dosing by bodyweight
Anchored to the most-cited research dose (3000 mcg @ 75 kg). Reference only.
| Bodyweight band | Reference dose range |
|---|---|
| <60 kg / <132 lb | 1870–2530 mcg |
| 60–75 kg / 132–165 lb | 2295–3105 mcg |
| 75–90 kg / 165–198 lb | 2805–3795 mcg |
| 90–105 kg / 198–231 lb | 3315–4485 mcg |
| >105 kg / >231 lb | 3825–5175 mcg |
Side effects to weigh against recovery benefit
- Hypersalivation (in dogs/cats)
- Mild emesis
- Lethargy
Also researched for
Educational use only
This calculator is provided for research and educational purposes. Outputs are derived from the values you enter. Always verify your math and consult a licensed physician before acting on any result.